WorldCat Identities

Piccart, Martine J.

Overview
Works: 52 works in 110 publications in 4 languages and 725 library holdings
Genres: Handbooks and manuals 
Roles: Editor, Author, Other, Author of introduction, Publishing director
Classifications: RC261, 616.994
Publication Timeline
.
Most widely held works by Martine J Piccart
Adjuvant breast cancer treatment( )

7 editions published between 2008 and 2009 in English and held by 362 WorldCat member libraries worldwide

Adjuvant therapy for breast cancer by Monica Castiglione( )

11 editions published in 2009 in English and held by 135 WorldCat member libraries worldwide

Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. "The adjuvant treatment of breast cancer has become standard of care. A spectrum of biologic and prognostic factors are considered before a therapeutic strategy is implemented. In this text leading investigators in the field discuss current management and critical investigative issues." Steven T. Rosen, M.D. Series Editor
Breast cancer and molecular medicine by Martine J Piccart( )

16 editions published in 2006 in English and Spanish and held by 70 WorldCat member libraries worldwide

Molecular-based medicine is taking center stage due to the increasing knowledge of breast cancer molecular biology. Treatment tailoring is no longer a dream for the future, but the main goal of current research. This book provides an overview of the most recent techniques, agents and approaches for breast cancer that contribute to the individualization of treatment. Current biomedical research focuses on facilitating the transfer of molecular biology knowledge into the clinical management of patients, leading to increased survival as well as improved quality of life. Particular attention is given in this book to organ-specific tailored approaches, specific populations, patients' preferences and rehabilitation. Also discussed in depth, are the respective roles of pharmacotherapeutics modelling, functional imaging, molecular staging, genomics and proteomics and their impact on the "re-classification" of breast cancer, as well as the clinical applications of basic science. The crucial issue of how to optimally integrate biological markers, new technologies and new diagnostic and therapeutic approaches into clinical trials and clinical practice is addressed.; Combining the contributions from authors who are well known experts in these fields with editorial comments, this book provides an overview of the latest achievements in breast cancer and their use in clinical practice
Handbook of HER2-targeted agents in breast cancer by Ricardo H Alvarez( )

12 editions published between 2013 and 2017 in English and held by 25 WorldCat member libraries worldwide

Annotation
Holland Frei cancer medicine 8 by Robert C Bast( )

5 editions published in 2017 in English and held by 19 WorldCat member libraries worldwide

"The original reference resource for medical oncologists, radiation oncologists, internists, and allied specialties involved in the treatment of cancer patients, Holland-Frei Cancer Medicine covers the ever-expanding field of current cancer science and clinical oncology practice. In this new ninth edition an outstanding editorial team from world-renowned medical centers continue to hone the leading edge forged in previous editions, with timely information on biology, immunology, etiology, epidemiology, prevention, screening, pathology, imaging, and therapy. Holland-Frei Cancer Medicine, Ninth Edition, brings scientific principles to clinical practice and is a testament to the ethos that innovative, comprehensive, multidisciplinary treatment of cancer patients must be grounded in a fundamental understanding of cancer biology. This ninth edition features hundreds of full color illustrations, photographs, tables, graphs and algorithms that enhance understanding of complex topics and make this text an invaluable clinical tool. Over 15 brand new chapters covering the latest advances, including chapters on Cancer Metabolism, Bioinformatics, Biomarker Based Clinical Trial Design, Health Services Research and Survivorship bring this comprehensive resource up-to-date. Each chapter contains overview boxes, select references and other pedagogic features, designed to make the content easy to access and absorb"--Provided by publisher
Optimising chemotherapy dose density and dose intensity : new strategies to improve outcomes in adjuvant therapy for breast cancer( Book )

4 editions published in 2000 in English and held by 16 WorldCat member libraries worldwide

Zielgerichtete Therapien beim Mammakarzinom : der Praxisguide by Nadia Harbeck( Book )

2 editions published between 2014 and 2015 in German and held by 11 WorldCat member libraries worldwide

Praxisorientiert: Entscheidungs- und Therapie-Algorithmen für den erfolgreichen Einsatz zielgerichteter Substanzen - Aktuell: Portrait der neusten auf dem Markt verfügbaren Substanzen, spezifische Nebenwirkungen und Maßnahmen - Individuell: Optimierte Behandlungswege beim frühen und fortgeschrittenen Mammakarzinom - Online: Regelmäßig aktualisierte und bewertete Informationen zu therapierelevanten Daten Neue Wege im Kampf gegen den Brustkrebs Substanzen, die Eigenschaften oder Signalwege von Tumorzellen gezielt blockieren (targeted therapies), ermöglichen neue und viel versprechende Behandlungsoptionen bei Krebs. Zunehmend stehen diese zielgerichteten Medikamente (z.B. monoklonale Antikörper, small molecules) auch zur Behandlung des frühen und fortgeschrittenen Mammakarzinoms zur Verfügung. Sie sind äußerst wirksam und bieten neue Chancen, bringen aber auch Fragestellungen im klinischen Alltag mit sich: Ihr optimaler Einsatz muss hinsichtlich Zeitpunkt, Dauer und Kombinationspräparaten definiert werden. Bisher unbekannte Nebenwirkungen und mögliche Wechselwirkungen mit anderen Arzneimitteln erfordern ein angepasstes Therapiemanagement. Renommierte Experten erläutern in diesem an der Praxis ausgerichteten Leitfaden die konkreten Einsatzmöglichkeiten der neuen Substanzen und beschreiben detailliert das Nebenwirkungsmanagement im klinischen Alltag. Ein hochaktuelles Referenzwerk für Gynäkologen, Onkologen und Internisten in Klinik und Praxis
2nd European Breast Cancer Conference : 26-30 September 2000, Brussels, Belgium by 2000, Bruxelles) European Breast Cancer Conference (2( Book )

3 editions published in 2000 in English and held by 10 WorldCat member libraries worldwide

Workshop proceedings / HER2 State-of-the-Art Conference : 21-23 November 1999 - Montreux, Switzerland by Montreux) HER2 State of the Art Conference (1999( Book )

3 editions published in 2001 in English and held by 8 WorldCat member libraries worldwide

Herceptin: HER2 status - changing clinical practice( Book )

1 edition published in 2001 in English and held by 7 WorldCat member libraries worldwide

Innovative approaches to the treatment of advanced breast cancer( Book )

3 editions published in 1997 in English and held by 7 WorldCat member libraries worldwide

Le cancer du sein un regard optimiste vers l'avenir by Jean-Marie Nogaret( Book )

2 editions published between 2005 and 2010 in French and held by 6 WorldCat member libraries worldwide

Innovations in the management of metastatic breast cancer : proceedings of an industrial satellite symposium at the 25th ESMO Congress, 13 October 2000, Hamburg, Germany by Symposium "Innovations in the Management of Metastatic Breast Cancer"( Book )

2 editions published in 2001 in English and held by 3 WorldCat member libraries worldwide

HER2 (neu) and trastuzumab (Herceptin) - paradigm of a targeted therapy( )

1 edition published in 2006 in English and held by 2 WorldCat member libraries worldwide

HER2 State-of-the-Art Conference : 21-23 November 1999, Montreaux, Switzerland : workshop proceedings by HER2 State-of-the-Art Conference( Book )

1 edition published in 2001 in English and held by 2 WorldCat member libraries worldwide

Thérapeutique du cancer by Jean-François Morère( Book )

1 edition published in 2001 in French and held by 2 WorldCat member libraries worldwide

Cet ouvrage est la deuxi me dition largement r vis e et augment e de Th rapeutique du cancer, dont la premi re dition est parue en 2002. Il est consacr, de mani re exhaustive, la strat gie th rapeutique des principaux cancers. Plus de soixante sp cialistes francophones, faisant autorit dans le domaine du cancer, font le point sur leurs connaissances et leur exp rience pour permettre de comprendre, diagnostiquer et traiter ces tumeurs. Cet ouvrage apporte une information compl te sur les concepts th rapeutiques courants pour le traitement des tumeurs solides et h matologiques. Il d crit les mod
Jumping higher: is it still possible? : the ALTTO trial challenge( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Trastuzumab, a humanized monoclonal antibody directed against HER2, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in the metastatic setting, as well as halving the recurrence rate and improving survival in HER2-positive early breast cancer. Lapatinib is an orally active, reversible, small-molecule tyrosine kinase inhibitor that potently inhibits both HER1 and HER2 tyrosine kinase activity. This agent is the most advanced in terms of clinical trials and has been shown to have a favorable safety profile. Owing to the promising activity seen in advanced breast cancer, lapatinib is the ideal candidate for testing in the adjuvant setting. Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) is a four-arm randomized trial designed to compare trastuzumab and lapatinib in women with early-stage HER2-positive breast cancer. Specifically, ALTTO will examine which anti-HER2 agent is more effective and which is their best schedule of administration, namely, what benefit will be derived by taking the drugs separately, in tandem order or in combination. Overall, 8000 patients will be enrolled worldwide
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. gefitinib) can delay endocrine resistance in breast cancer. A double-blind, placebo-controlled, phase II trial investigated whether adding gefitinib (G) to anastrozole (A) would improve outcome in advanced breast cancer (ABC). METHODS: Postmenopausal pre-treated hormone receptor-positive ABC patients (locally recurrent or metastatic) were 1:1 randomized to A (1 mg/d) plus G 250 mg/d or plus placebo (P). Patients who had prior treatment with an aromatase inhibitor in metastatic setting or with trastuzumab, anti-EGFR or anti-VEGF agents were excluded. Treatment was given until disease progression, unacceptable toxicity or patient withdrawal. Progression-free survival (PFS) rate at 1 year was assessed according to Response Evaluation Criteria in Solid Tumours, version 1.0. RESULTS: Of 108 planned patients, 71 were recruited (36 in A/G and 35 in A/P). The trial closed prematurely due to slow recruitment; 31 patients had prior chemotherapy and 53 prior endocrine therapy (all except one received tamoxifen); 60% in adjuvant and 16% in metastatic setting received tamoxifen; 59 patients had visceral disease. Median follow-up was 18 months. PFS rate at 1 year was 35% for A/G and 32% for A/P arm. Objective responses were six (22%) in the A/G and nine (28%) in the A/P arm. Median duration of response was 13.8 and 18.6 months in the A/G and A/P arms, respectively. Fatigue (35%), diarrhoea (31%), rash (32%), dry skin (27%), and arthralgia/myalgia (27%) were the commonest adverse events in the A/G arm. CONCLUSIONS: This phase II study, although prematurely closed, did not show a signal that adding G to A improves PFS at 1 year and its use is not supported. Gastrointestinal and skin toxicities were more pronounced with G resulting in premature therapy interruption in almost 1 in 3 patients (ClinicalTrials.gov number, NCT00066378)
Textbook of medical oncology by Francesco Cavalli( Book )

1 edition published in 2009 in Undetermined and held by 2 WorldCat member libraries worldwide

This completely revised third edition of a key source of reference for all working in the field of oncology has added important new chapters and illustrations to keep it at the forefront of cancer medicine
Abstract book / 2nd European Breast Cancer Conference : 26-30 September 2000, Brussels, Belgium by 2000, Bruxelles) European Breast Cancer Conference (2( Book )

1 edition published in 2000 in English and held by 2 WorldCat member libraries worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.49 (from 0.03 for Holland Fr ... to 0.98 for A European ...)

Adjuvant breast cancer treatment Adjuvant therapy for breast cancer
Covers
Adjuvant therapy for breast cancerBreast cancer and molecular medicineTextbook of medical oncology
Alternative Names
Gebhart, Martine J. Piccart-.

Gebhart, Martine J. Piccart- 1953-

Gebhart, Martine Piccart-.

Martine Piccart Belgian physician, oncologist and medical researcher

Martine Piccart Belgisch oncologe

Piccart-Gebhart, M.

Piccart-Gebhart, M. J.

Piccart-Gebhart, Martine.

Piccart-Gebhart, Martine, 1953-

Piccart, M.

Piccart, M. 1953-

Piccart, M. J. 1953-

Piccart, Martine.

Piccart, Martine J. 1953-

Languages